SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like NIH Hooks Up With 11 Top Biopharmas for $215 Million Cancer Moonshot Deal October 12, 2017 FDA Green Lights Gilead's Vosevi, With a Black Box Warning Attached July 18, 2017 Bay Area's IMPAX Labs Surges on Merger Buzz September 21, 2017